NASDAQ : INO
Inovio Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.6024 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 62.29M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 211.96M |
| Enterprise Value | 183.29M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 103.40M |
| Shares Outstanding | 103.40M |
| Shares Change (YoY) | +92.40% |
| Shares Change (QoQ) | +18.11% |
| Owned by Insiders (%) | 0.38% |
| Owned by Institutions (%) | 31.94% |
| Float | 95.79M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 2.88 |
| PB Ratio | 11.35 |
| P/TBV Ratio | 14.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.00 |
| Quick Ratio | 0.92 |
| Debt / Equity | 1.83 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -409.87% |
| Return on Assets (ROA) | -84.23% |
| Return on Invested Capital (ROIC) | -192.15% |
| Return on Capital Employed (ROCE) | -836.58% |
| Weighted Average Cost of Capital (WACC) | 11.62% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$602,027 |
| Employee Count | 112 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.61 |
| 52-Week Price Change | -75.21% |
| 50-Day Moving Average | 1.14 |
| 200-Day Moving Average | 1.26 |
| Relative Strength Index (RSI) | 27.17 |
| Average Volume (20 Days) | 8,350,701 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 21.30M |
| Short Previous Month | 20.82M |
| Short % of Shares Out | 20.60% |
| Short % of Float | 22.24% |
| Short Ratio (days to cover) | 7.27 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -48.49M |
| Operating Income | -79.26M |
| Pretax Income | -67.43M |
| Net Income | -67.43M |
| EBITDA | -77.93M |
| EBIT | -79.26M |
| Earnings Per Share (EPS) | -$1.03 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 36.67M |
| Total Debt | 8.00M |
| Net Cash | 28.67M |
| Net Cash Per Share | $0.28 |
| Equity (Book Value) | 4.37M |
| Book Value Per Share | 0.05 |
| Working Capital | -1,810 |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -80.58M |
| Capital Expenditures | -195,395 |
| Depreciation & Amortization | 1.33M |
| Net Borrowing | n/a |
| Free Cash Flow | -80.78M |
| FCF Per Share | -$0.78 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -92.40% |
| Shareholder Yield | -92.40% |
| Earnings Yield | -50.43% |
| FCF Yield | -129.69% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $4.00 |
| Price Target Difference | 95.12% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 965.76% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jan 25, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -56 |
| Piotroski F-Score | n/a |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |